Weight Management in Cancer Patients: Studies presented at ASCO evaluated the use of semaglutide (and tirzepatide) for weight loss in women with early-stage (IIII) breast cancer
grants and personal fees from Biogen Inc., grants and personal fees from Teva, grants from Alexion, grants and personal fees from Bayer HealthCare, grants from Elan, grants and personal fees from EMD Serono Canada Inc., grants from GlaxoSmithKline, grants from MedDay, grants and personal fees from Novartis, grants from Ono, grants and personal fees from Roche, grants from Sanofi-Aventis, personal fees from NeuroRx, personal fees from Allergan, personal fees from Sanofi-Genzyme, personal fees from Merz, outside the submitted work
[19] [22] Patients with multiple risk factors require enhanced monitoring and may benefit from more frequent follow-up during semaglutide titration
Essential Extras: The original version of Bydureon has been discontinued, but Bydureon BCISE (extended release) remains available and is administered weekly
UCO Medical Clinic provides tiered weight loss injection packages to meet different needs
